Search

Your search keyword '"Issoufaly, Tazime"' showing total 13 results
Start Over Author "Issoufaly, Tazime"
13 results on '"Issoufaly, Tazime"'

1. Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study

Author

Kuner, Charlotte, Stättermayer, Albert Friedrich, Trauner, Michael, Hernández-Gea, Virginia, Payancé, Audrey, Roux, Olivier, Issoufaly, Tazime, Valainathan, Shantha, de Broucker, Chloé, Torres, María, Stefanescu, Horia, Platon, Monica, Fodor, Andreea, Nicoara-Farcau, Oana, Bianchini, Marcello, Guasconi, Tomas, Vanwolleghem, Thomas, Schoenmakers, Lotte, Vonghia, Luisa, Labenz, Christian, Dajti, Elton, Colecchia, Luigi, Vanderschueren, Emma, Sandmann, Lisa, Greenfield, Helena, Jachs, Mathias, Odriozola, Aitor, Turon, Fanny, Moga, Lucile, Téllez, Luis, Fischer, Petra, Saltini, Dario, Kwanten, Wilhelmus J, Grasso, Maria, Llop, Elba, Mendoza, Yuly P, Armandi, Angelo, Thalhammer, Julia, Pardo, Carlos, Colecchia, Antonio, Ravaioli, Federico, Maasoumy, Benjamin, Laleman, Wim, Presa, José, Schattenberg, Jörn M, Berzigotti, Annalisa, Calleja, José L, Calvaruso, Vincenza, Francque, Sven, Schepis, Filippo, Procopet, Bogdan, Albillos, Agustín, Rautou, Pierre-Emmanuel, García-Pagán, Juan C, Puente, Ángela, Fortea, José I, Reiberger, Thomas, and Mandorfer, Mattias

Published
2024
Full Text
View/download PDF

2. Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study

Author

Arab, Juan Pablo, Díaz, Luis Antonio, Baeza, Natalia, Idalsoaga, Francisco, Fuentes-López, Eduardo, Arnold, Jorge, Ramírez, Carolina A., Morales-Arraez, Dalia, Ventura-Cots, Meritxell, Alvarado-Tapias, Edilmar, Zhang, Wei, Clark, Virginia, Simonetto, Douglas, Ahn, Joseph C., Buryska, Seth, Mehta, Tej I., Stefanescu, Horia, Horhat, Adelina, Bumbu, Andreea, Dunn, Winston, Attar, Bashar, Agrawal, Rohit, Haque, Zohaib Syed, Majeed, Muhammad, Cabezas, Joaquín, García-Carrera, Inés, Parker, Richard, Cuyàs, Berta, Poca, Maria, Soriano, German, Sarin, Shiv K., Maiwall, Rakhi, Jalal, Prasun K., Abdulsada, Saba, Higuera-de la Tijera, María Fátima, Kulkarni, Anand V., Rao, P Nagaraja, Guerra Salazar, Patricia, Skladaný, Lubomir, Bystrianska, Natália, Prado, Veronica, Clemente-Sanchez, Ana, Rincón, Diego, Haider, Tehseen, Chacko, Kristina R., Cairo, Fernando, de Sousa Coelho, Marcela, Romero, Gustavo A., Pollarsky, Florencia D., Restrepo, Juan Carlos, Castro-Sanchez, Susana, Toro, Luis G., Yaquich, Pamela, Mendizabal, Manuel, Garrido, Maria Laura, Narvaez, Adrián, Bessone, Fernando, Marcelo, Julio Santiago, Piombino, Diego, Dirchwolf, Melisa, Arancibia, Juan Pablo, Altamirano, José, Kim, Won, Araujo, Roberta C., Duarte-Rojo, Andrés, Vargas, Victor, Rautou, Pierre-Emmanuel, Issoufaly, Tazime, Zamarripa, Felipe, Torre, Aldo, Lucey, Michael R., Mathurin, Philippe, Louvet, Alexandre, García-Tsao, Guadalupe, González, José Alberto, Verna, Elizabeth, Brown, Robert S., Roblero, Juan Pablo, Abraldes, Juan G., Arrese, Marco, Shah, Vijay H., Kamath, Patrick S., Singal, Ashwani K., and Bataller, Ramon

Published
2021
Full Text
View/download PDF

5. WED-071 The association of hepatocyte large extracellular vesicles with plasma biomarkers levels improve prediction of mortality in patients with cirrhosis

Author

Payancé, Audrey, primary, Biquard, Louise, additional, Thietart, Sara, additional, Silva-Junior, Gilberto, additional, Tanguy, Marion, additional, Issoufaly, Tazime, additional, Levi, Cristina, additional, Bissonnette, Julien, additional, Valla, Dominique, additional, Durand, Francois, additional, Carlos García-Pagán, Juan, additional, and Rautou, Pierre-Emmanuel, additional

Published
2024
Full Text
View/download PDF

6. Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study

Author

Jachs, Mathias, Odriozola, Aitor, Turon, Fanny, Moga, Lucile, Téllez, Luis, Fischer, Petra, Saltini, Dario, Kwanten, Wilhelmus J, Grasso, Maria, Llop, Elba, Mendoza, Yuly P, Armandi, Angelo, Thalhammer, Julia, Pardo, Carlos, Colecchia, Antonio, Ravaioli, Federico, Maasoumy, Benjamin, Laleman, Wim, Presa, José, Schattenberg, Jörn M, Berzigotti, Annalisa, Calleja, José L, Calvaruso, Vincenza, Francque, Sven, Schepis, Filippo, Procopet, Bogdan, Albillos, Agustín, Rautou, Pierre-Emmanuel, García-Pagán, Juan C, Puente, Ángela, Fortea, José I, Reiberger, Thomas, Mandorfer, Mattias, Kuner, Charlotte, Stättermayer, Albert Friedrich, Trauner, Michael, Hernández-Gea, Virginia, Payancé, Audrey, Roux, Olivier, Issoufaly, Tazime, Valainathan, Shantha, de Broucker, Chloé, Torres, María, Stefanescu, Horia, Platon, Monica, Fodor, Andreea, Nicoara-Farcau, Oana, Bianchini, Marcello, Guasconi, Tomas, Vanwolleghem, Thomas, Schoenmakers, Lotte, Vonghia, Luisa, Labenz, Christian, Dajti, Elton, Colecchia, Luigi, Vanderschueren, Emma, Sandmann, Lisa, and Greenfield, Helena

Abstract

In patients with compensated advanced chronic liver disease (cACLD), risk of clinically significant portal hypertension (CSPH) can be estimated by applying non-invasive tests such as liver stiffness measurement (LSM), platelet count, and, in some cases, BMI. We aimed to assess the diagnostic utility of spleen stiffness measurement (SSM) at 100 Hz as a standalone non-invasive test for CSPH and to evaluate its incremental value compared with the ANTICIPATE±NASH model in patients with cACLD.

Published
2024
Full Text
View/download PDF

7. Nicotine patches in patients on mechanical ventilation for severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial

Author

Labro, Guylaine, Tubach, Florence, Belin, Lisa, Dubost, Jean-Louis, Osman, David, Muller, Grégoire, Quenot, Jean-Pierre, da Silva, Daniel, Zarka, Jonathan, Turpin, Matthieu, Mayaux, Julien, Lamer, Christian, Doyen, Denis, Chevrel, Guillaume, Plantefeve, Gaétan, Demeret, Sophie, Piton, Gaël, Manzon, Cyril, Ochin, Evelina, Gaillard, Raphael, Dautzenberg, Bertrand, Baldacini, Mathieu, Lebbah, Said, Miyara, Makoto, Pineton de Chambrun, Marc, Amoura, Zahir, Combes, Alain, Palmyre, Jessica, Gimeno, Linda, Kone, Assitan, Vialette, Cedric, Slimi, Ouramdane, Chommeloux, Juliette, Lefevre, Lucie, Schmidt, Matthieu, Hekimian, Guillaume, Luyt, Charles-Edouard, Stiel, Laure, Dureau, Anne-Florence, Khaldoun, Kuteifan, Eid, Hanna, Baldacini, Matthieu, Zyberfajn, Cecile, Manson, Julien, Charrier, Nathanael, Balabanian, Angelique, Contou, Damien, Pajot, Olivier, Fraisse, Megan, Desaint, Paul, Sarfati, Florence, Fartoukh, Muriel, Voirot, Guillaume, Elabbabi, Alexandre, Djibre, Michel, Desnos, Cyrielle, Garcon, Pierre, van Vong, Ly, Issad, Andrea, Pillot, Bertrand, Reither, Delphine, Rouge, Patrick, Foliot, Pascale, Bendjamar, Lynda, Pointurier, Valentin, Winiszewski, Hadrien, Capellier, Gilles, Navellou, Jean-Christophe, Tapponnier, Romain, Panicucci, Emilie, Morand, Lucas, Dellamonica, Jean, Saccheri, Clement, Weiss, Nicolas, Marois, Clemence, Le Guennec, Loic, Rohaut, Benjamin, Ensenat, Luis, Billiou, Cecilia, Aroca, Maria, Baron, Marie, Demoule, Alexandre, Beurton, Alexandra, Bureau, Come, Decavele, Maxens, Dres, Martin, Bayle, Frederique, Le, Quoc Viet, Liron, Lionel, Putegnat, Jean-Baptiste, Salord, Francois, Andreu, Pascal, Slimani, Hakim, Roudeau, Baptiste, Labruyere, Marie, Jacquier, Marine, Anguel, Nadia, Ayed, Soufia, Durand, Edgard, Guerin, Laurent, Lai, Christopher, Aboab, Jerome, Alviset, Sophie, Laine, Laurent, Azzi, Mathilde, Issoufaly, Tazime, Tric, Laurent, Knani, Lyes, Boumezrag, Chahrazad Bey, Viault, Nicolas, Barbier, Francois, Boulain, Thierry, Kamel, Toufik, Nay, Mai-Anh, Tollec, Sophie, Nguyen, an Hung, Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service de Département de santé publique [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier René Dubos - 6, avenue de l’Ile de France 95303 CERGY-PONTOISE, Service de Pneumologie et Réanimation Respiratoire [AP-HP Hôpital Bicêtre] (DHU TORINO), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)-Centre de Référence de l'Hypertension Pulmonaire Sévère, Centre Hospitalier Régional d'Orléans (CHRO), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), réanimation et soins continus [CH Saint-Denis], Centre Hospitalier de Saint-Denis [Ile-de-France], Grand Hôpital de l'Est Francilien (GHEF), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Département Médico-Universitaire APPROCHES, Sorbonne Université (SU), Neurophysiologie Respiratoire Expérimentale et Clinique (UMRS 1158), Institut Mutualiste de Montsouris (IMM), Hôpital l'Archet, Centre Hospitalier Universitaire de Nice (CHU Nice), Centre Hospitalier Sud Francilien, Centre Hospitalier Victor Dupouy, REanimation et Soins intensifs du Patient en Insuffisance Respiratoire aigüE [CHU Pitié-Salpêtrière] (GRC RESPIRE), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de Réanimation, Médipole Lyon Villeurbanne. Service de réanimation. 158 rue Léon Blum. 69100 VILLEURBANNE, France, Service de médecine intensive-réanimation Hôpital Simone Veil, Eaubonne, France, GHU Paris Psychiatrie et Neurosciences, Université Paris Cité (UPCité), Service de Pneumologie - R3S [CHU Pitié-Salpêtrière] (SPMIR-R3S), Institut Arthur Vernes, Unité de Recherche Clinique des hôpitaux Pitié-Salpêtrière – Charles Foix [CHU Pitié Salpêtrière] (URC PSL-CFX), CHU Charles Foix [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Direction de la Recherche Clinique et de l'Innovation [AP-HP] (DRCI), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Médecine Interne 2, maladies auto-immunes et systémiques [CHU Pitié-Salpêtrière], Institut E3M [CHU Pitié-Salpêtrière], Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Service de Réanimation Médicale [CHU Pitié-Salpétrière], and TUBACH, Florence

Subjects
Adult, Male, Nicotine, [SDV]Life Sciences [q-bio], Acute respiratory failure, Critical Care and Intensive Care Medicine, MESH: Nicotine, Nicotinic receptor, Double-Blind Method, MESH: COVID-19, Humans, MESH: SARS-CoV-2, MESH: Double-Blind Method, MESH: Respiration, Artificial, MESH: Treatment Outcome, MESH: Humans, SARS-CoV-2, COVID-19, MESH: Adult, Respiration, Artificial, Ventilation, MESH: Male, [SDV] Life Sciences [q-bio], Intensive Care Units, Treatment Outcome, Artificial, MESH: Intensive Care Units, Female, Randomized trial, MESH: Female
Abstract

Epidemiologic studies have documented lower rates of active smokers compared to former or non-smokers in symptomatic patients affected by coronavirus disease 2019 (COVID-19). We assessed the efficacy and safety of nicotine administered by a transdermal patch in critically ill patients with COVID-19 pneumonia.In this multicentre, double-blind, placebo-controlled trial conducted in 18 intensive care units in France, we randomly assigned adult patients (non-smokers, non-vapers or who had quit smoking/vaping for at least 12 months) with proven COVID-19 pneumonia receiving invasive mechanical ventilation for up to 72 h to receive transdermal patches containing either nicotine at a daily dose of 14 mg or placebo until 48 h following successful weaning from mechanical ventilation or for a maximum of 30 days, followed by 3-week dose tapering by 3.5 mg per week. Randomization was stratified by centre, non- or former smoker status and Sequential Organ Function Assessment score ( or ≥ 7). The primary outcome was day-28 mortality. Main prespecified secondary outcomes included 60-day mortality, time to successful extubation, days alive and free from mechanical ventilation, renal replacement therapy, vasopressor support or organ failure at day 28.Between November 6th 2020, and April 2nd 2021, 220 patients were randomized from 18 active recruiting centers. After excluding 2 patients who withdrew consent, 218 patients (152 [70%] men) were included in the analysis: 106 patients to the nicotine group and 112 to the placebo group. Day-28 mortality did not differ between the two groups (30 [28%] of 106 patients in the nicotine group vs 31 [28%] of 112 patients in the placebo group; odds ratio 1.03 [95% confidence interval, CI 0.57-1.87]; p = 0.46). The median number of day-28 ventilator-free days was 0 (IQR 0-14) in the nicotine group and 0 (0-13) in the placebo group (with a difference estimate between the medians of 0 [95% CI -3-7]). Adverse events likely related to nicotine were rare (3%) and similar between the two groups.In patients having developed severe COVID-19 pneumonia requiring invasive mechanical ventilation, transdermal nicotine did not significantly reduce day-28 mortality. There is no indication to use nicotine in this situation.

Published
2022
Full Text
View/download PDF

9. Extracorporeal CO2 Removal in Acute Exacerbation of COPD Not Responding to Non-Invasive Ventilation: a Single Center Experience

Author

Azzi, Mathilde, primary, Aboab, Jerome, additional, Alviset, Sophie, additional, Ushmorova, Daria, additional, Ferreira, Luis, additional, Ioos, Vincent, additional, Memain, Nathalie, additional, Issoufaly, Tazime, additional, Lermuzeaux, Mathilde, additional, Laine, Laurent, additional, Serbouti, Rita, additional, and Silva, Daniel, additional

Published
2021
Full Text
View/download PDF

10. Plasma protein glycomics combined with circulating fragments of cytokeratin-18 are reliable biomarkers to diagnose alcoholic hepatitis

Author

Xavier, Verhelst, primary, Geerts, Anja, additional, Meuris, Leander, additional, Degroote, Helena, additional, Tanguy, Marion, additional, Davy, Hortense, additional, Issoufaly, Tazime, additional, Durand, François, additional, Callewaert, Nico, additional, Van Vlierberghe, Hans, additional, and Rautou, Pierre-Emmanuel, additional

Published
2020
Full Text
View/download PDF

13. Extracorporeal CO 2 removal in acute exacerbation of COPD unresponsive to non-invasive ventilation.

Author

Azzi M, Aboab J, Alviset S, Ushmorova D, Ferreira L, Ioos V, Memain N, Issoufaly T, Lermuzeaux M, Laine L, Serbouti R, and Silva D

Subjects
Carbon Dioxide, Humans, Length of Stay, Respiration, Artificial, Noninvasive Ventilation, Pulmonary Disease, Chronic Obstructive therapy
Abstract

Background: The gold-standard treatment for acute exacerbation of chronic obstructive pulmonary disease (ae-COPD) is non-invasive ventilation (NIV). However, NIV failures may be observed, and invasive mechanical ventilation (IMV) is required. Extracorporeal CO₂ removal (ECCO₂R) devices can be an alternative to intubation. The aim of the study was to assess ECCO₂R effectiveness and safety., Methods: Patients with consecutive ae-COPD who experienced NIV failure were retrospectively assessed over two periods of time: before and after ECCO₂R device implementation in our ICU in 2015 (Xenios AG)., Results: Both groups (ECCO₂R: n=26, control group: n=25) were comparable at baseline, except for BMI, which was significantly higher in the ECCO₂R group (30 kg/m² vs 25 kg/m²). pH and PaCO₂ significantly improved in both groups. The mean time on ECCO₂R was 5.4 days versus 27 days for IMV in the control group. Four patients required IMV in the ECCO₂R group, of whom three received IMV after ECCO₂R weaning. Seven major bleeding events were observed with ECCO₂R, but only three led to premature discontinuation of ECCO₂R. Eight cases of ventilator-associated pneumonia were observed in the control group. Mean time spent in the ICU and mean hospital stay in the ECCO₂R and control groups were, respectively, 18 vs 30 days, 29 vs 49 days, and the 90-day mortality rates were 15% vs 28%., Conclusions: ECCO₂R was associated with significant improvement of pH and PaCO₂ in patients with ae-COPD failing NIV therapy. It also led to avoiding intubation in 85% of cases, with low complication rates., Trial Registration Number: ClinicalTrials.gov, NCT04882410. Date of registration 12 May 2021, retrospectively registered.https://www.clinicaltrials.gov/ct2/show/NCT04882410., Competing Interests: Competing interests: Rita Serbouti, from Fresenius Medical Care France, Medical affairs, helped train staff in Extracorporeal CO2 Removal Device and contributed to proofreading this paper. No financial support from the industry was received., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results